Abstract
Prolyl oligopeptidase or prolyl endopeptidase (PREP; EC 3.4.21.26) is an atypical serine protease that hydrolyses peptides and peptide hormones after proline in peptides up to around 30 residues long. Evidence suggests an involvement in learning and memory, and the enzyme is implicated in diseases including amnesia and depression. The first crystal structures determined, of the porcine enzyme, provided direct insight into the mechanisms of substrate size selectivity, substrate specificity, and catalysis. However in these structural studies the enzyme is in a closed state, even in the absence of ligand, leaving questions as to how substrates and products can enter and exit the enclosed central cavity that houses the active site. More recent crystal structures of bacterial PREP have captured the enzyme in an open state, revealing the true extent and nature of the structural dynamics involved, and illuminating an induced fit mode of catalysis and regulation. Molecular modeling has further contributed to our understanding of the conformational changes that occur during catalysis. Here we review the data that has led to our current understanding of the structure and dynamics of this biologically and pharmaceutically important enzyme.
Keywords: Conformational changes, crystal structures, induced fit, molecular dynamics, prolyl endopeptidase, prolyl oligopeptidase, PREP, Multiple Sclerosis, Sphingomonas capsulata, Aeromonas punctata, ApPREP D622N-ZPP complex, Electron Microscopy
CNS & Neurological Disorders - Drug Targets
Title: Prolyl Oligopeptidase Structure and Dynamics
Volume: 10 Issue: 3
Author(s): Dean Rea and Vilmos Fulop
Affiliation:
Keywords: Conformational changes, crystal structures, induced fit, molecular dynamics, prolyl endopeptidase, prolyl oligopeptidase, PREP, Multiple Sclerosis, Sphingomonas capsulata, Aeromonas punctata, ApPREP D622N-ZPP complex, Electron Microscopy
Abstract: Prolyl oligopeptidase or prolyl endopeptidase (PREP; EC 3.4.21.26) is an atypical serine protease that hydrolyses peptides and peptide hormones after proline in peptides up to around 30 residues long. Evidence suggests an involvement in learning and memory, and the enzyme is implicated in diseases including amnesia and depression. The first crystal structures determined, of the porcine enzyme, provided direct insight into the mechanisms of substrate size selectivity, substrate specificity, and catalysis. However in these structural studies the enzyme is in a closed state, even in the absence of ligand, leaving questions as to how substrates and products can enter and exit the enclosed central cavity that houses the active site. More recent crystal structures of bacterial PREP have captured the enzyme in an open state, revealing the true extent and nature of the structural dynamics involved, and illuminating an induced fit mode of catalysis and regulation. Molecular modeling has further contributed to our understanding of the conformational changes that occur during catalysis. Here we review the data that has led to our current understanding of the structure and dynamics of this biologically and pharmaceutically important enzyme.
Export Options
About this article
Cite this article as:
Rea Dean and Fulop Vilmos, Prolyl Oligopeptidase Structure and Dynamics, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653850
DOI https://dx.doi.org/10.2174/187152711794653850 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design A Recent Look into Natural Products that have Potential to Inhibit Cholinesterases and Monoamine Oxidase B: Update for 2010-2019
Combinatorial Chemistry & High Throughput Screening p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Editorial: [Hot Topic The Biochemistry/Toxicity of Aluminum (Guest Editors: Christopher A. Shaw & Lucija Tomljenovic)]
Current Inorganic Chemistry (Discontinued) NF-κB Signature on the Aging Wall
Current Drug Metabolism A Missed Proteome in Living Organisms: A Hyppo System
Current Proteomics Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Commentary (Research Highlights: Wnt-Signalling: A New Direction for Alzheimer Disease?)
CNS & Neurological Disorders - Drug Targets Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
Current Drug Targets Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Emerging Promise of Therapeutic Approaches Targeting Mitochondria in Neurodegenerative Disorders
Current Neuropharmacology Ursolic Acid and Oleanolic Acid: Pentacyclic Terpenoids with Promising Anti-Inflammatory Activities
Recent Patents on Inflammation & Allergy Drug Discovery Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Sulfur-Containing Compounds in Protecting Against Oxidant-Mediated Lung Diseases
Current Medicinal Chemistry Is there a Role for Sodium Orthovanadate in the Treatment of Diabetes?
Current Diabetes Reviews Recent Advances in the Treatment Strategies of Friedreich’s Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms
Current Pharmaceutical Design Microbiome-Based Therapies in Parkinson’s Disease: Can Tuning the Microbiota Become a Viable Therapeutic Strategy?
CNS & Neurological Disorders - Drug Targets